Bactigon/KELT-7 is a world-first, non-antibiotic polymer that prevents bacterial biofilm formation. Developed by the University of Nottingham and Angel Guard, this material inhibits the growth of deadly pathogens without relying on antibiotics or toxic agents, thereby avoiding the development of antimicrobial resistance. Its versatile design allows for use in diverse applications, including water systems, sanitary fixtures, and plumbing, effectively reducing infection risks in critical infrastructure.
Bactigon/KELT-7 is a world-first, non-antibiotic anti-biofilm polymer developed through a collaboration between the University of Nottingham and the water management company Angel Guard. By preventing the formation of bacterial biofilms—complex communities of bacteria that protect pathogens from natural defenses and antibiotics—this material significantly reduces the risk of dangerous infections. Its unique, antibiotic-free mechanism avoids contributing to the critical issue of antimicrobial resistance, offering a sustainable approach to enhancing public health and safety.
The polymer is designed for extreme versatility and durability, making it suitable for a wide range of applications:
The technology is at a stage of commercial deployment and practical application. It has been developed into a functional polymer for use in water systems, sanitary fixtures, fittings, and plumbing components. It is currently being utilized in real-world contexts, such as coating components like o-rings for potable water systems, and is positioned as a market-ready solution to protect infrastructure and end-users from biofilm-related health risks. Based on its successful transition from fundamental research to industrial partnership and product launch, this is assessed as TRL 9.
The University of Nottingham is a comprehensive public research university and Russell Group member based in Nottingham, with campuses in China and Malaysia, enabling international collaboration and talent pipelines. Industry partners engage through an on-campus research and technology park that co-locates companies with university groups, plus shared-use facilities and pilot spaces for scale-up. Integration with a major NHS hospital system supports clinical trials and translation, while placements and professional programs connect companies with student and graduate talent. Research is supported by competitive funding from UKRI research councils and Innovate UK, with added support through NHS partnerships and European programs. A dedicated technology transfer office manages IP, licensing, and spinout formation.